SCHEMBL605463

SCHEMBL605463

NC(CO)C(O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
ADRA2A P08913 1/20 0.56
ADRA2C P18825 1/20 0.56
LMNA P02545 1/20 0.56
HIF1A Q16665 1/20 0.56
ALDH1A1 P00352 2/20 0.54
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
SLC6A3 Q01959 1/20 0.50
AOC3 Q16853 4/20 0.48
DPP4 P27487 2/20 0.44
F2 P00734 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15916220 1.00 KDM4E (0.56) KDM4EADRA2AADRA2CLMNAHIF1A
SCHEMBL1162359 1.00 KDM4E (0.56) KDM4EADRA2AADRA2CLMNAHIF1A
SCHEMBL145000 1.00 KDM4E (0.56) KDM4EADRA2AADRA2CLMNAHIF1A
SCHEMBL5043328 1.00 KDM4E (0.56) KDM4EADRA2AADRA2CLMNAHIF1A
SCHEMBL2065907 1.00 KDM4E (0.56) KDM4EADRA2AADRA2CLMNAHIF1A
SCHEMBL147622 1.00 KDM4E (0.56) KDM4EADRA2AADRA2CLMNAHIF1A
SCHEMBL3363663 1.00 KDM4E (0.56) KDM4EADRA2AADRA2CLMNAHIF1A
Bromide SCHEMBL9771320 0.98 KDM4E (0.54) KDM4EADRA2AADRA2CLMNAHIF1A
Hydrochloric Acid SCHEMBL9779186 0.98 ALDH1A1 (0.57) KDM4EADRA2AADRA2CLMNAHIF1A
Benzoic Acid SCHEMBL6048463 0.87 DAO (0.48) KDM4EADRA2AADRA2CLMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025108372-A1 TEMPERATURE-RESISTANT POLYMER AND PREPARATION METHOD THEREFOR, AND USE OF CYCLIC IMIDE DIOL COMPOUND 元素驱动(杭州)生物科技有限公司 2025-05-30 WO claimed
WO-2025108371-A1 COPOLYMER WITH IMPROVED STRENGTH AND PREPARATION METHOD THEREFOR 元素驱动(杭州)生物科技有限公司 2025-05-30 WO claimed
CN-113330004-B Differential solubility driven asymmetric conversion process for substituted 2H-chromene-3-carboxylic acids 株式会社AskAt 2023-11-17 CN claimed
EP-3906232-B1 PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS ASKAT INC (JP) 2023-05-10 EP claimed
CN-109180843-B Non-phthalate compounds as electron donors for polyolefin catalysts 美国台塑公司 2022-03-01 CN claimed
CN-110407964-B Catalyst component for olefin polymerization and preparation method thereof 中国石油化工股份有限公司 2021-09-21 CN claimed
CN-110407963-B Catalyst component for olefin polymerization and preparation method thereof 中国石油化工股份有限公司 2021-09-21 CN claimed
CN-110437435-B One-step synthesis method of terminal amino-functionalized polyether 华南理工大学 2021-08-10 CN claimed
US-11065238-B2 Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) 2021-07-20 US claimed
EP-2938594-B1 METHOD FOR THE SYNTHESIS OF ALPHA/ALPHA-PRIME-ALCOXYLATED GLYCEROL LINEAR CARBONIC ESTERS CHRYSO (FR) 2020-06-17 EP claimed
EP-0130633-B1 Process for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives ZAMBON SPA (IT) 1996-10-09 EP claimed
EP-0678506-A2 Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives ZAMBON GROUP S.p.A. (IT) 1995-10-25 EP claimed
EP-0677511-A2 Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives ZAMBON GROUP S.p.A. (IT) 1995-10-18 EP claimed
EP-0423705-B1 Process for the stereochemical inversion of (2S,3S)-2-amino-3-phenyl-1,3-propanediols into their (2R,3R) enantiomers ZAMBON SPA (IT) 1995-01-11 EP claimed
US-5367094-A Hydrogenation for dehydroxylation of 2-amino-1-phenyl-1,3-propanediol in the presence of strong acid YUKONG, LTD. (KR) 1994-11-22 US claimed
EP-0423705-A2 Process for the stereochemical inversion of (2S,3S)-2-amino-3-phenyl-1,3-propanediols into their (2R,3R) enantiomers ZAMBON GROUP S.p.A. (IT) 1991-04-24 EP claimed
US-4814477-A SALT FORMATION, CRYSTALLIZATION, HYDROLYSIS OCE-NEDERLAND B.V. (NL) 1989-03-21 US claimed
EP-0085023-A1 Process for the separation of enantiomers by partition between liquid phases CIBA-GEIGY AG (CH) 1983-08-03 EP claimed
US-4335057-A 4-(2',2,2'-Trihalogenoethyl)-cyclobutane-1-sulfonic acid salts with optically active bases CIBA-GEIGY CORPORATION (US) 1982-06-15 US claimed
US-4299967-A Process for producing optically active 2-(2,2-dihalogenovinyl)-cyclopropane-1-carboxylic acids substituted in the 3-position, and derivatives thereof, as well as novel 4-(2,2,2-trihalogenoethyl)-cyclobutane-1-sulfonic acid salts CIBA-GEIGY CORPORATION (US) 1981-11-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11065238-B2 Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases GBA1, SMN1; SMN2, GAA KDM4E 3898/4885ADRA2A 4123/4885ADRA2C 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.